Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH‐mutant and 1p/19q‐codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report. Issue 1 (14th December 2022)